

FOR IMMEDIATE RELEASE

Media contacts

Lisa Merkl
Houston Methodist
+1 832 667 5916
lmerkl@houstonmethodist.org

Eileen Leahy
Elsevier
+1 732 238 3628
ajpmedia@elsevier.com

Study finds COVID-19 convalescent plasma therapy safe, with 76 percent of patients improving

First peer-reviewed publication on US trial results from Houston Methodist published in The American Journal of Pathology

Houston and Philadelphia, June 2, 2020 – The country’s first convalescent plasma transfusion trial results have been peer-reviewed and published, showing 19 out of 25 patients improving with the treatment and 11 discharged from the hospital. On March 28, Houston Methodist became the first academic medical center in the nation to transfuse plasma from recovered COVID-19 patients into two critically ill patients.


With no adverse side effects caused by the plasma transfusion, the study concluded that convalescent plasma is a safe treatment option for patients with severe COVID-19 disease. To date, this is the largest cohort worldwide assessed for outcomes pertaining to convalescent plasma transfusion for COVID-19. The [findings are described in a paper](#) appearing in press on May 26 in [The American Journal of Pathology](#). This is the first peer-reviewed publication on convalescent plasma use in the United States.

[James M. Musser, MD, PhD](#), Chair of the Department of Pathology and Genomic Medicine at Houston Methodist, is the corresponding author on the study, titled “Treatment of COVID-19 patients with convalescent plasma.” [Eric Salazar, MD, PhD](#), Assistant Professor of Pathology and Genomic Medicine with the Houston Methodist Research Institute, is the Principal Investigator who led the project to treat critically ill COVID-19 patients with convalescent plasma.

“While physician scientists around the world scrambled to test new drugs and treatments against the COVID-19 virus, convalescent serum therapy emerged as potentially one of the most promising strategies,” Dr. Musser said. “With no proven treatments or cures for COVID-19 patients, now was the time in our history to move ahead rapidly.”

Patients were first treated under emergency use guidelines (eIND) from the US Food and Drug Administration (FDA) and then received approval April 3 from the FDA to open up the trial to more patients as an investigational new drug (IND). This extraordinarily rapid approval granted by the FDA opened up access to convalescent plasma treatment for COVID-19 patients.

The century-old therapeutic approach dates back to at least as early as 1918 to fight the Spanish Flu and more recently was used with some success during the 2003 SARS pandemic, the 2009 influenza H1N1 pandemic and the 2015 Ebola outbreak in Africa. Following a study early on in the COVID-19 pandemic, where a handful of critically ill patients in China showed improvement, an interdisciplinary team of Houston Methodist physician scientists and health care workers rapidly targeted the COVID-19 virus with convalescent serum therapy.



Caption: Houston Methodist physician scientists (left to right) Eric Salazar, MD, PhD, and James M. Musser, MD, PhD, discuss their convalescent plasma trial for treating COVID-19, the results of which were the first in the US to be peer-reviewed and published. Credit: Houston Methodist

Additional findings during this trial revealed patient outcomes following plasma therapy were very similar to recently published results of patients treated on a compassionate-use basis with the antiviral drug remdesivir. The research team also concluded that any observed complications were consistent with findings reported for COVID-19 disease progression and did not result from the plasma transfusions. The study's overall findings were consistent with several other small case studies of convalescent plasma use for severe COVID-19 that have been recently reported.

Ultimately, although the convalescent plasma therapy administered on the front lines at Houston Methodist was implemented for emergency treatment, the study's authors recognize the important need for controlled clinical trials to determine its therapeutic efficacy. A randomized controlled trial is currently being considered at Houston Methodist where they would also look more closely at variables such as timing of the transfusion after the onset of symptoms, the number and volume of transfusions adjusted for patient biometrics, antibody levels in donor plasma and numerous other parameters needed to effectively evaluate how to optimize this therapy. This would help address some questions, including whether patients would have better outcomes if plasma transfusions were administered sooner after the onset of symptoms.

Not all plasma recipients transfused so far at Houston Methodist were part of this first trial. Since late March, when the first patients were infused with convalescent plasma, Houston Methodist has treated 74 critically ill COVID-19 patients, 50 of whom have been discharged from the hospital and are recovering.

More than 150 recovered COVID-19-infected individuals donated their plasma, many of them continuing to do so frequently.

Notes for editors

The article is "Treatment of COVID-19 patients with convalescent plasma," by Eric Salazar, Katherine K. Perez, Madiha Ashraf, Jian Chen, Brian Castillo, Paul A. Christensen, Taryn Eubank, David W. Bernard, Todd N. Eagar, S. Wesley Long, Sishir Subedi, Randall J. Olsen, Christopher Leveque, Mary R. Schwartz, Monisha Dey, Cheryl Chavez-East, John Rogers, Ahmed Shehabeldin, David Joseph, Guy Williams, Karen Thomas, Faisal Masud, Christina Talley, Katharine G. Dlouhy, Bevin Valdez Lopez, Curt Hampton, Jason Lavinder, Jimmy D. Gollihar, Andre C. Maranhao, Gregory C. Ippolito, Matthew Ojeda Saavedra, Concepcion C. Cantu, Prasanti Yerramilli, Layne Pruitt, James M. Musser (<https://doi.org/10.1016/j.ajpath.2020.05.014>). It will appear in *The American Journal of Pathology*, volume 190, Issue 8 (August 2020) published by [Elsevier](#).

The article is openly available at [https://ajp.amjpathol.org/article/S0002-9440\(20\)30257-1/pdf](https://ajp.amjpathol.org/article/S0002-9440(20)30257-1/pdf).

This study was supported by funding from the National Institutes of Health (grants AI146771-01 and AI139369-01), the Fondren Foundation, the National Institute of Allergy and Infectious Diseases (Contract Number 75N93019C00050), the Army Research Office (Cooperative Agreement W911NF-12-1-0390), Houston Methodist Hospital and Houston Methodist Research Institute.

Elsevier's [Novel Coronavirus Information Center](#) provides the latest early stage and peer-reviewed research on the novel coronavirus and COVID-19. All resources are free to access and include guidelines for clinicians and patients. The Information Center links to the [Coronavirus Hub](#) on ScienceDirect, with more than 28,000 articles relevant to coronavirus, SARS, and MERS freely available. The center also links to a Healthcare Hub with resources for clinicians treating COVID-19 patients. www.elsevier.com/connect/coronavirus-information-center

About *The American Journal of Pathology*

[The American Journal of Pathology](#), official journal of the [American Society for Investigative Pathology](#), published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. <http://ajp.amjpathol.org>

About Elsevier

[Elsevier](#) is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we're committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including [ScienceDirect](#), [Scopus](#), [SciVal](#), [ClinicalKey](#) and [Sherpath](#). Elsevier publishes over 2,500 digitized journals, including [The Lancet](#) and [Cell](#), 39,000 e-book titles and many iconic reference works, including [Gray's Anatomy](#). Elsevier is part of [RELX](#), a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com